Novartis initiates study on DII235 for elevated lipoprotein(a)
Novartis is conducting a clinical trial to evaluate the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
Asset / Drug
Drug and asset intelligence for DII235 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.